Bergenbio ASA (BGBIO) - Total Liabilities
Based on the latest financial reports, Bergenbio ASA (BGBIO) has total liabilities worth Nkr19.75 Million NOK (≈ $2.08 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Bergenbio ASA (BGBIO) net asset momentum to track the company's year-over-year net asset growth rate.
Bergenbio ASA - Total Liabilities Trend (2013–2024)
This chart illustrates how Bergenbio ASA's total liabilities have evolved over time, based on quarterly financial data.
Bergenbio ASA Competitors by Total Liabilities
The table below lists competitors of Bergenbio ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Turbon AG
F:TUR
|
Germany | €15.83 Million |
|
KWESST MICRO SYS.INC.
F:62UA
|
Germany | €4.09 Million |
|
Stavely Minerals Ltd
AU:SVY
|
Australia | AU$732.40K |
|
FLYNN Gold Ltd
AU:FG1
|
Australia | AU$762.33K |
|
Caely Holdings Bhd
KLSE:7154
|
Malaysia | RM23.51 Million |
|
Rockhopper Exploration
LSE:RKH
|
UK | GBX114.05 Million |
|
Identi Healthcare Ltd
TA:IDNT
|
Israel | ILA3.92 Million |
|
AcouSort AB
ST:ACOU
|
Sweden | Skr3.21 Million |
Liability Composition Analysis (2013–2024)
This chart breaks down Bergenbio ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BGBIO company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bergenbio ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bergenbio ASA (2013–2024)
The table below shows the annual total liabilities of Bergenbio ASA from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr33.09 Million ≈ $3.48 Million |
-29.38% |
| 2023-12-31 | Nkr46.86 Million ≈ $4.93 Million |
-40.08% |
| 2022-12-31 | Nkr78.21 Million ≈ $8.23 Million |
+18.84% |
| 2021-12-31 | Nkr65.81 Million ≈ $6.93 Million |
-3.18% |
| 2020-12-31 | Nkr67.97 Million ≈ $7.15 Million |
+34.27% |
| 2019-12-31 | Nkr50.62 Million ≈ $5.33 Million |
+21.85% |
| 2018-12-31 | Nkr41.55 Million ≈ $4.37 Million |
+22.24% |
| 2017-12-31 | Nkr33.99 Million ≈ $3.58 Million |
+59.81% |
| 2016-12-31 | Nkr21.27 Million ≈ $2.24 Million |
+20.52% |
| 2015-12-31 | Nkr17.64 Million ≈ $1.86 Million |
-421.46% |
| 2014-12-31 | Nkr-5.49 Million ≈ $-577.60K |
-195.23% |
| 2013-12-31 | Nkr5.76 Million ≈ $606.54K |
-- |
About Bergenbio ASA
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat drug resistant, metastatic cancers, and respiratory disease in Norway. It develops BGBIL025, a JAK2 inhibitor indicated, which is in Ph1b/2a for treatment of the bone marrow disorder myelofibrosis. The company was incorporated in 2007 and is based in Bergen, Norway.